Biogen Inc. executives sought on Wednesday to ease investors’ concerns over the recent failure of one of the company’s investigational Alzheimer's drugs.

from MarketWatch.com - Top Stories https://on.mktw.net/2UZCUz6
via IFTTT
from MarketWatch.com - Top Stories https://on.mktw.net/2UZCUz6
via IFTTT
Kommentare
Kommentar veröffentlichen